Income Statement
The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.
UnitedHealth Group Inc., consolidated income statement
US$ in millions
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
UnitedHealth Group experienced consistent revenue growth between 2021 and 2025, although the rate of growth appears to be moderating in the later years. While revenues increased steadily, profitability metrics demonstrate a more complex pattern, with initial gains followed by a decline in recent periods. Medical costs, the largest expense, have increased proportionally with revenues, impacting gross profit and ultimately net earnings.
- Revenue Growth
- Revenues, encompassing premiums, products, and services, increased from US$285.273 billion in 2021 to US$443.647 billion in 2025, representing a cumulative growth of 55.5%. However, the annual growth rate decelerated from 12.9% in 2022 to 8.1% in 2023, 9.4% in 2024, and 11.8% in 2025. This suggests a potential saturation point or increased competitive pressure.
- Profitability Analysis
- Gross profit increased from US$67.328 billion in 2021 to US$86.869 billion in 2023, but then decreased to US$78.997 billion in 2025. This decline is attributable to the rapid increase in cost of revenues, which outpaced revenue growth in the latter periods. Earnings from operations followed a similar trend, peaking at US$32.358 billion in 2023 before falling to US$18.964 billion in 2025. Net earnings attributable to UnitedHealth Group common shareholders mirrored this pattern, decreasing from US$22.381 billion in 2023 to US$12.056 billion in 2025.
- Cost Structure
- Medical costs represent a substantial portion of revenues, increasing from US$186.911 billion in 2021 to US$313.995 billion in 2025. The cost of products sold and cost of revenues also exhibited consistent increases throughout the period. Operating costs also increased, from US$42.579 billion to US$59.592 billion, contributing to the overall pressure on profitability. Depreciation and amortization remained relatively stable as a percentage of revenue.
- Other Income and Expenses
- Investment and other income fluctuated, with a peak of US$5.202 billion in 2024. Interest expense increased steadily from US$1.660 billion in 2021 to US$4.002 billion in 2025, reflecting potentially higher debt levels or increased borrowing costs. A significant loss on the sale of a subsidiary and subsidiaries held for sale was recorded in 2024 (US$8.310 billion) and a smaller loss in 2025 (US$265 million), impacting earnings before income taxes.
- Tax Rate
- The effective tax rate varied across the years. The provision for income taxes as a percentage of earnings before income taxes was approximately 20.4% in 2021, 21.4% in 2022, 20.5% in 2023, 23.8% in 2024, and 12.9% in 2025. The lower tax rate in 2025 partially offset the decline in earnings before income taxes, but did not fully mitigate the decrease in net earnings.
In summary, while UnitedHealth Group demonstrated strong revenue growth over the five-year period, increasing costs and specific events like the subsidiary sale negatively impacted profitability in the later years. The company experienced a notable decline in net earnings attributable to common shareholders from 2023 to 2025, suggesting a need for cost management strategies or revenue diversification.
AI Ask an analyst for more